Evidence map›Paper›PMID 35073986›Full record

Trial reportTrials2022

A randomized double-blind cross-over trial to study the effects of resistant starch prebiotic in chronic kidney disease (ReSPECKD).

Maryam Shamloo, Rebecca Mollard, Haizhou Wang, Kulwant Kingra, Navdeep Tangri, Dylan MacKay

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Trials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04961164 (A Randomized Double-Blind Cross-over Trial to Study the Effects of Resistant Starch Prebiotic Effects in Chronic Kidney Disease), which is not on this map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04961164 nacompletednot on this map

A Randomized Double-Blind Cross-over Trial to Study the Effects of Resistant Starch Prebiotic Effects in Chronic Kidney Disease (ReSPECKD)

TypeinterventionalSponsorUniversity of ManitobaRan2022 to 2024Enrolled50ConditionsChronic Kidney DiseasesArmsResistant Potato Starch, Corn Starch, Corn Starch, Resistant Potato Starch
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Consumption of SolnulNutrients · 2023
    Trial
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Maryam ShamlooChronic Disease Innovation Centre, Seven Oaks General Hospital, Winnipeg, MB, Canada.
Rebecca MollardChronic Disease Innovation Centre, Seven Oaks General Hospital, Winnipeg, MB, Canada.
Haizhou WangChronic Disease Innovation Centre, Seven Oaks General Hospital, Winnipeg, MB, Canada.
Kulwant KingraMax Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada.
Navdeep TangriChronic Disease Innovation Centre, Seven Oaks General Hospital, Winnipeg, MB, Canada.
Dylan MacKayDepartment of Human Nutritional Sciences, University of Manitoba, Winnipeg, MB, Canada. dylan.mackay@umanitoba.ca.ORCID http://orcid.org/0000-0002-0751-1634
Seven Oaks General Hospital · CAUniversity of Manitoba · CA

Funding

Mitacs IT15871
6 · The paper itself

Abstract

backgroundChronic kidney disease (CKD) is associated with a reduced quality of life and an increased risk of kidney failure, cardiovascular events, and all-cause mortality. Accumulation of nitrogen-based uremic toxins leads to worsening of symptoms in individuals with CKD. Many uremic toxins, such as indoxyl and p-cresol sulphate, are produced exclusively by the gut microbiome through the proteolytic digestion of aromatic amino acids. Strategies to reduce the production of these toxins by the gut microbiome in individuals with CKD may lessen symptom burden and delay the onset of dialysis. One such strategy is to change the overall metabolism of the gut microbiome so that less uremic toxins are produced. This can be accomplished by manipulating the energy source available to the microbiome. Fermentable carbohydrates which reach the gut microbiome, like resistant starch (RS), have been shown to inhibit or reduce bacterial amino acid metabolism. This study aims to investigate the effects of resistant potato starch (RPS) as a prebiotic in individuals with CKD before the onset of dialysis.

methodsThis is a double-blind, randomized two-period crossover trial. Thirty-six eligible participants will consent to follow a 26-week study regimen. Participants will receive 2 sachets per day containing either 15 g of RPS (MSPrebiotic, resistant potato starch treatment) or 15 g cornstarch (Amioca TF, digestible starch control). Changes in blood uremic toxins will be investigated as the primary outcome. Secondary outcomes include the effect of RPS consumption on symptoms, quality of life and abundance, and diversity and functionality of the gut microbiome. DISCUSSION: This randomized trial will provide further insight into whether the consumption of RPS as a prebiotic will reduce uremic toxins and symptoms in individuals who have CKD.

trial registrationClinicalTrials.gov NCT04961164 . Registered on 14 July 2021.

Indexed as

Renal Insufficiency, ChronicResistant StarchCross-Over StudiesHumansPrebioticsQuality of LifeUremic ToxinsPrebioticsResistant StarchUremic ToxinsChronic kidney diseaseGut microbiomeRandomized controlled trialResistant starchUremic toxins

Identifiers

PMID35073986
PMCPMC8785497
OpenAlexW4225470994

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.